0001209191-21-023135.txt : 20210325 0001209191-21-023135.hdr.sgml : 20210325 20210325213639 ACCESSION NUMBER: 0001209191-21-023135 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210325 FILED AS OF DATE: 20210325 DATE AS OF CHANGE: 20210325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Edris Badreddin CENTRAL INDEX KEY: 0001786966 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 21774382 MAIL ADDRESS: STREET 1: C/O SPRINGWORKS THERAPEUTICS, INC. STREET 2: 100 WASHINGTON BLVD. CITY: STAMFORD STATE: CT ZIP: 06902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVE, 54TH FLR. CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-739-6451 MAIL ADDRESS: STREET 1: C/O ORBIMED ADVISORS LLC STREET 2: 601 LEXINGTON AVE, 54TH FLR. CITY: NEW YORK STATE: NY ZIP: 10022 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-03-25 0 0001710072 Edgewise Therapeutics, Inc. EWTX 0001786966 Edris Badreddin C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE. BOULDER CO 80303 1 0 0 0 Common Stock 19820 D Stock Option (Right to Buy) 0.39 2028-04-26 Common Stock 13960 D Stock Option (Right to Buy) 0.64 2029-11-14 Common Stock 17236 D Stock Option (Right to Buy) 0.71 2030-09-01 Common Stock 7605 D Stock Option (Right to Buy) 1.93 2030-12-15 Common Stock 10463 D Stock Option (Right to Buy) 1.93 2031-02-03 Common Stock 66477 D 1/4th of the shares subject to the option became vested and exercisable on March 4, 2018 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. 1/48th of the shares subject to the option became vested and exercisable on November 16, 2019 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. 1/48th of the shares subject to the option became vested and exercisable on October 2, 2020 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. 1/48th of the shares subject to the option became vested and exercisable on January 3, 2021 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. The shares of Common Stock underlying the option are subject to an early exercise provision and are immediately exercisable. 1/36th of the shares subject to the option will become vested on March 3, 2021 and 1/36th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. Exhibit 24 - Power of Attorney /s/John R. Moore Attorney-in-Fact for Badreddin Edris 2021-03-25 EX-24.3_975592 2 poa.txt POA DOCUMENT POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of Edgewise Therapeutics, Inc. (the Company), hereby constitutes and appoints Kevin Koch, Ph.D., R. Michael Carruthers and John R. Moore, and each of them, as the true and lawful attorney-in-fact of the undersigned to: 1. prepare, execute in the name of the undersigned and on the behalf of the undersigned, and submit the Securities and Exchange Commission (the SEC) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain EDGAR codes and passwords enabling the undersigned to make electronic filings with the SEC or reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; 2. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and 2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate. The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended). This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the holdings of the undersigned of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of March, 2021. Signature: /s/ Badreddin Edris, Ph.D. Print Name: Badreddin Edris, Ph.D.